对摘要标题“[177Lu]Lu-edotreotide与依维莫司在1级或2级胃肠胰神经内分泌肿瘤患者中的疗效和安全性：COMPETE 3期试验”的更正。

IF 4.1 4区医学 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Neuroendocrinology Pub Date : 2025-04-02 DOI:10.1111/jne.70025

引用次数: 0

摘要

第22届ENETs年会，2025年3月5日至7日。[J]神经内分泌杂志。2015；37 (S1): e70018。“Results”部分第二句中，中位PFS的p值和风险比数据不正确。正确的数据是：“p = 0.022”和“HR: 0.67”。我们为这个错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction to abstract title “Efficacy and safety of [177Lu]Lu-edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial”

22nd Annual ENETs Conference, 5th–7th March 2025. J Neuroendocrinol. 2025; 37(S1): e70018.

In the second sentence of the “Results” section, the data of the p-value and hazard ratio of the median PFS are incorrect. The correct data are: “p = 0.022” and “HR: 0.67”.

We apologize for this error.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Neuroendocrinology 医学-内分泌学与代谢

CiteScore

6.40

自引率

6.20%

发文量

137

审稿时长

4-8 weeks

期刊介绍： Journal of Neuroendocrinology provides the principal international focus for the newest ideas in classical neuroendocrinology and its expanding interface with the regulation of behavioural, cognitive, developmental, degenerative and metabolic processes. Through the rapid publication of original manuscripts and provocative review articles, it provides essential reading for basic scientists and clinicians researching in this rapidly expanding field. In determining content, the primary considerations are excellence, relevance and novelty. While Journal of Neuroendocrinology reflects the broad scientific and clinical interests of the BSN membership, the editorial team, led by Professor Julian Mercer, ensures that the journal’s ethos, authorship, content and purpose are those expected of a leading international publication.